A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis who have not been previously treated with disease-modifying antirheumatic drugs

Trial Profile

A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis who have not been previously treated with disease-modifying antirheumatic drugs

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Apremilast (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms PALACE-4
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 17 Jun 2017 Results of pooled analysis of PALACE-1,2,3 and 4 studies assessing long term improvement in physical functions presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 16 Sep 2016 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
    • 26 Aug 2015 Planned End Date changed from 1 Jul 2017 to 1 Jun 2017 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top